Analysis reveals Egypt's partnerships with WHO and industry enhance pharmaceutical regulation, indicating potential for broader collaboration across Africa.
AbstractEgypt’s achievement of Maturity Level 3 (ML3) for medical products, as assessed by the WorldHealth Organization’s (WHO) Global Benchmarking Tool (GBT), highlights a significantmilestone in Africa’s pharmaceutical regulation landscape. This paper explores the collaborativestrategies employed by the Egyptian Drug Authority (EDA), including partnerships with theWHO and industry stakeholders, to strengthen local manufacturing and regulatory frameworks.Additionally, it examines the challenges faced by African National Regulatory Authorities(NRAs), such as limited autonomy, resource constraints, and disjointed regulatory systems. Thepaper concludes with recommendations for fostering regulatory harmonization, enhancingautonomy, and leveraging WHO initiatives to strengthen pharmaceutical regulations andimprove health outcomes across Africa.
No takes yet. Share an insight, caveat, or question.
Olawuyi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: